This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Department of Pharmaceuticals (DoP) has issued a new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, permitting pharmacompanies to provide brand reminders such as informational and education items and free samples to medical professionals with restrictions on sample packs and total value.
At 99% of pharmacompanies, that's a huge no-no. On top of this, “the company also revealed that the Federal Trade Commission and the Securities and Exchange Commission had opened two new, separate investigations into the troubled biotech. At 99% of pharmacompanies, that’s a huge no-no.
In today’s competitive healthcare landscape, PPC campaigns (Pay-Per-Click advertising) have emerged as a critical lever for pharma marketers aiming to deliver timely, targeted, and measurable impact. Gone are the days when print ads and in-person detailing alone could carry a brand. Moreover, PPC isnt just about Google Ads.
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.
The drug led to impressive blood sugar and body weight drops in clinical trials. The approval for tirzepatide—which Lilly will market under the brand name Mounjaro—isn’t for weight loss but Type 2 diabetes. Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. A matter of trust?
Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharmabrands digital presence. So, how can pharmacompanies use content marketing to engage HCPs and patients effectively ? Lets dive in.
SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharmacompanies, according to Indegene. Your physician audience should be segmented by parameters that are important to the success of your brand.
This strategic move transformed Actavis into one of the largest pharmacompanies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.
In recent years, pharmacompanies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between reps and HCPs during and post-pandemic. What is meant by an HCP portal? How can this impact patient care?
Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulation in a phase 3 trial. Results from a trial in first-line NSCLC are due in early 2023.
In 2019, drugs within the oncology therapeutic area accounted for $143 billion in branded pharmaceutical sales, equalling approximately 20% of all global pharmaceutical sales, according to McKinsey. One of the means of more quickly discovering and progressing R&D candidates that pharma is looking into is AI technology.
With millions of healthcare professionals (HCPs) and patients active on platforms like LinkedIn, Twitter, Facebook, and Instagram, pharmabrands can no longer afford to stay silent. Effective social media strategies allow pharmacompanies to: Build trust with HCPs and patients. Short video clips with expert insights.
Whether you’re a large pharmacompany or a small, emerging one, communication is key. Mark has developed the commercial strategy and leading market access, marketing and multi-channel sales teams at launch for a German biotech company, CO.DON AG, a specialized leader in cell therapies.
The combined company will operate under the BehaVR brand, and starts operations with a $13 million cash injection from a Series B financing led by Oxford Science Enterprises and Optum Ventures with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures, and Thornton Capital.
Among these, influencer marketing has emerged as a powerful tool for pharmacompanies seeking to build trust and foster engagement with their target audiences. By leveraging influencer networks, pharmaceutical brands can effectively convey their messages, promote their products, and ultimately improve patient outcomes.
Armed with these insights, life sciences companies can develop patient-centric solutions that will lead to more successful products. Taking an engaged approach has clear benefits, including improved trial retention and development of PROs that can support market-entry and market access. Read the full article here.
In many cases, pharmacompanies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. PDF scale and reformulation challenge manufacturers. Innovative solutions to complex challenges.
It powers drug discovery, clinical trials, and operational performance. Pharmacompanies generate lots of data and bring in other data to support their actions but not all of it gets used which is where we come in,” says Thomas Kurian, head of new markets at Treasure Data, which powers some of the largest companies in pharmaceuticals. “The
Digital advertising campaigns allow pharmaceutical brands to connect with their audiences at critical moments in the healthcare journey. How Digital Ads Are Changing Pharma Marketing Precision Targeting : AI and data analytics allow ads to be shown to HCPs based on specialty, prescribing behavior, and practice location.
Digital advertising campaigns allow pharmaceutical brands to connect with their audiences at critical moments in the healthcare journey. How Digital Ads Are Changing Pharma Marketing Precision Targeting : AI and data analytics allow ads to be shown to HCPs based on specialty, prescribing behavior, and practice location.
In the second quarter alone the vaccine, branded as Comirnaty, raked in $7.8 Disappointing late-stage trials of CureVac’s jab meant there was no competitive advantage, while Sanofi said the dominance of current vaccines made penetration in the market difficult. Meanwhile, China and Russia have rolled out state-owned vaccines.
Consultations and clinical trials are often few and far between. This new information can help pharma increase adherence by improving the quality of treatment and creating patient-centred programs and materials. More frequent data points are needed to get the whole picture on rare diseases.
But how can pharmabrands optimize their digital assets while staying compliant with industry regulations? Imagine a pharma website as a digital waiting room. By refining user experience, messaging, and engagement strategies, pharmacompanies can increase prescription intent, patient adherence, and HCP interaction rates.
Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.
Today, digital platforms like LinkedIn and Instagram connect brands with healthcare professionals (HCPs) and patients alike. Patient-Centric Approaches: The shift towards patient empowerment has revolutionized the way pharmabrands communicate. How can pharmacompanies personalize their campaigns?
Understanding Cost-Per-Action in Pharma Cost-Per-Action (CPA) is a performance-based advertising model where advertisers pay only when a specific action is completed. How It Works: Pharmacompanies define an “action,” such as an HCP downloading a clinical study or a patient enrolling in a treatment program.
Despite limited clinical evidence, a higher inclination of patients towards marijuana has caused several pharmacompanies and regulatory authorities to look at the medical use of marijuana in a new light. Moreover, now BioSteel has signed Kansas City Chiefs quarterback Patrick Mahomes as the endorser of the brand. and Canada.
Following a worldwide Phase 3 trial of BNT162b2 and results indicating the vaccine to be more than 90 per cent effective in preventing Covid-19 cases where participants have shown no evidence of being infected with coronavirus , Pfizer and BioNTech are anticipating further regulatory decisions and approvals to be made around the world.
A marketing network refers to the interconnected channels and strategies pharmacompanies use to reach their target audiences. Why it Matters Efficient Reach: A well-structured network ensures that branded drugs like Keytruda or Dupixent are promoted effectively to the right audience.
A pharmacompany formerly led by ‘pharma bro’ Martin Shkreli has settled a long-running lawsuit with the US federal government over massive price increases for an off-patent drug treatment for people with an HIV-related disease.
The Phase 3 trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed Covid-19 cases have been accrued. The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19. “We
According to Real Chemistry, there are currently 119 active GLP-1 agonist clinical trials, with 53 in Phases III or IV, across more than 60 potential new indications for GLP-1 treatment.
“Therefore, it is essential companies understand the clinical outcomes that are meaningful to patients, and the quality-of-life trade-offs people are willing to make to achieve those outcomes.”. Every activity is included in the map and shared across brands and business functions. Mapping and managing the patient journey.
The contribution of key pharmacompanies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size. Who would have thought that consumption of gluten can trigger an autoimmune disorder?
These technologies enable pharmaceutical companies to analyze vast amounts of data quickly, identify potential drug candidates, and optimize clinical trials, ultimately accelerating the time-to-market for new therapies. Content marketing is another powerful tool in the pharma marketer’s arsenal.
Pharma Adoption is Slower and More Complex We surveyed experts from 20 companies within the pharmaceutical industry. The respondents represented a diverse set of stakeholders from pharmacompanies, agencies, tech companies, and publishers.
Metoclopramide , sold under the brand name Reglan , is the first and only FDA-approved therapy for the treatment of Diabetic Gastroparesis. However, double-blind trials have reported results on the contrary with practically no alleviation of symptoms. Moreover, the company is also evaluating the drug in the treatment of COVID-19.
Pharma Adoption is Slower and More Complex We surveyed experts from 20 companies within the pharmaceutical industry. The respondents represented a diverse set of stakeholders from pharmacompanies, agencies, tech companies, and publishers.
My background for decades now is in the pharma marketing and branding space, working with all sorts of pharma products, devices, diagnostics. Do you connect patients with the clinical trial folks? I think the clinical trial model is a perfect model that is broken and needs to be enhanced. Bob (83Bar): Yes, we do.
Pharmacompanies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. During the course of my treatments and my trials, and afterwards, I was the expert in how I wanted to manage my life.”.
Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. Robin (Guest): I’ve been so excited for this one thank you so much for having me.
Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. Robin (Guest): I’ve been so excited for this one thank you so much for having me.
Last year, the company added clinical trials to the list with the launch of CVS Health Clinical Trial Services , an initiative that works with pharmacompanies on clinical trial recruitment and even hosts trial sites at certain retail locations. This interview has been edited for length and clarity.
So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content